Cambridge Team's AI-Designed Vaccine: A Potential Breakthrough to Save Lives

Researchers say artificial intelligence (AI) has been used to develop a "radically new" type of vaccine that could combat a wide range of viruses and prevent pandemics.

According to BBC Chinese, a team at the University of Cambridge says this is the first time a key component of a vaccine has been entirely designed by AI and tested in humans.

The vaccine is designed to fight all coronaviruses, including all variants of SARS-CoV-2, as well as viruses that infect animals but could trigger the next pandemic.

The research is still in its early stages, but the team has already begun developing related vaccines for influenza and Ebola.

Vaccines work by teaching the body to recognize an infection and build resistance. However, some viruses are adept at changing their appearance (mutating), which can render vaccines ineffective quickly. This is why COVID-19 and winter flu vaccines need regular updates.

Professor Jonathan Heeney from the University of Cambridge stated: "We've always been playing catch-up... Our goal is to get ahead of the virus, even to the point of preventing future pandemics or new disease outbreaks."

**How was the new vaccine created?**

Typically, vaccines are designed based on existing virus strains. Cambridge researchers collected the known genetic sequences of multiple coronaviruses. This genetic data was analyzed by AI, which designed a "super-antigen" capable of training the immune system to provide protection against the entire virus family, even if the virus mutates or a new virus jumps from animals to humans.

Professor Heeney said this is the first time an AI-designed antigen has been tested in humans. He said the technology "surprised us all" and offers "amazing possibilities for human well-being."

He told the BBC: "It's about creating vaccines that protect us, not just against today's viruses, but also against new viruses that could cause future pandemics. This marks a fundamental shift in how we approach pandemics."

The first trial recruited 39 people, primarily to assess the vaccine's safety. A second study will involve around 200 people to further understand its effect on training the immune system.

Results published in the UK's "Journal of Infection" indicated that the vaccine's effect on the immune system was "moderate," but it still generated widespread interest and excitement.

Professor Saul Faust from the University of Southampton, who participated in part of the trial, said this AI-designed approach "definitely has potential" and is "very exciting."

The Cambridge team is also conducting animal experiments to develop a universal seasonal flu vaccine that wouldn't need annual updates, as well as a vaccine for H5N1 bird flu to prevent it from evolving from its current impact on birds into a human pandemic.

They are also researching vaccines for viral hemorrhagic fevers, including Ebola. The current outbreak in the Democratic Republic of Congo is caused by a virus strain for which no vaccine exists.

Professor Andy Pollard, director of the Oxford Vaccine Group, who was not involved in the study, said the approach has shown compelling evidence in animal studies.

He said: "This data is very intriguing, even exceeding expectations, because no one anticipated such an immune response could be generated."

Professor Pollard believes AI will bring a "disruptive breakthrough" to vaccine research. AI tools can predict how the immune system will react to a vaccine, dramatically speeding up development and "saving lives."